WHO Grants Emergency Use Listing —The World Health Organization (WHO) on May 6 granted an emergency use listing (EUL) to Sinopharm for the vaccine developed by state-owned China National Pharmaceutical Group (Sinopharm Group) with Beijing Institute of Biological Products under Sinopharm's vaccine and bioscience subsidiary China National Biotec Group (CNBG). WHO recommended the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks. The EUL marked the WHO's first granted to a non-Western vaccine developer. 2020 Status: Conditional approval granted –China's National Medical Products Administration (NMPA) on December 30 granted conditional approval to the vaccine developed by state-owned China National Pharmaceutical Group (Sinopharm Group) through its vaccine and bioscience subsidiary China National Biotec Group (CNBG) with CNBG's Beijing Institute of Biological Products.